Drugs / CMAB007
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07246252 | Mar → Sep 2024 | — | Taizhou Mabtech Pharmaceutical Co.,Ltd | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT06365879 | Jun 2024 → Jan 2026 overdue | chronic idiopathic urticaria | Taizhou Mabtech Pharmaceutical Co.,Ltd | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03468790 | May 2018 → Jan 2021 | allergic asthma | Shanghai Biomabs Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CMAB007 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07246252 ↗ |
| Modality | Monoclonal antibody | “CMAB007(recombinant humanized anti-IgE monoclonal antibody for injection )” NCT03468790 ↗ |
| Route | Subcutaneous | “300mg, SC, Q4W” NCT06365879 ↗ |